Replies to post #387933 on NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

Complete fiction.

The UCLA Medical School is behind DCVax-L.

Look at the following quotes during the talks by Dr. Linda Liau and Dr. Leia Nghiemphu.

Dr. Linda Liau (Fellow of the National Academy of Medicine) talking about the DCVax-L therapy at the UAB on November 6th, 2020: "It is good for the patients."

Dr. Leia Nghiemphu of the UCLA School of Medicine on December 4th, 2020 at the UCLA Brain Tumor Virtual Conference: "There are many different types of vaccines... Here at UCLA, we use the dendritic cell vaccine."

The UCLA School of Medicine is currently using DCVax-L in their current Combo Project I trials.

[learningcurve2020]

Liau said in that Malloy interview that she and others need some large - order it up menu style facilities for not just DC's but other therapeutics too. Powers may be helping to fulfill that vision at the expense of retail.

But it is puzzling that UCLA is building out their own facility while bypassing Cognate.

[The Danish Dude]

Thanks for yet another update on your traumas regarding the DCVax-L trial setup, your chronical worries about Linda Liaus relationship with NWBO.

The Mount Sinai video had DCVax-L ALL over it. Why? Because ATL-DC IS DCVax-L.

This has been proven countless times, but lets just go over it once more.







ATLnsider states that ATL-DC is the same as DCVax. It is the brand trademark owned by NWBO, which can not be used by UCLA.





ATLnsider attaches documentation for the brand trademark being owned by NWBO. He referres to an article wherein this is stated and that he also spoke with UCLA about this.





UCLA's ATL-DC vaccine IS NWBOs DCVax. It's the generic form of NWBO's branded vaccine, let’s walk through some other documentation:



https://vimeo.com/529196354



From muee88:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163400357

https://www.uclahealth.org/personalized-vaccine-may-increase-longterm-survival-in-people-with-deadliest-form-of-brain-cancer

Here is another older article that provides a bit more about the relationship between UCLA and NWBO.

https://www.uclahealth.org/personalized-vaccine-may-increase-longterm-survival-in-people-with-deadliest-form-of-brain-cancer

“The research was supported by Northwest Biotherapeutics, Inc., which manufactures DCVax-L, and by the National Cancer Institute through the UCLA brain cancer program, which was recently designated a Specialized Program of Research Excellence by the NCI.”

So, it’s likely that if NWBO was funding the research, there would have been an agreement that all products of that research would be assigned to NWBO. Again, this agreement is like not to be public record.